Deepali Gotur

Tango Therapeutics (United States) — United States

Medicine · Health Sciences

9h-index437citations73works2.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Science, Research, and Medicine(20), RNA Research and Splicing(16), Ubiquitin and proteasome pathways(15), RNA and protein synthesis mechanisms(13), Biotechnology and Related Fields(13)

Publications73 total

Supplementary Figure S2 from Ubiquitinated PCNA Drives USP1 Synthetic Lethality in Cancer
2025Open Access
Supplementary Tables from Ubiquitinated PCNA Drives USP1 Synthetic Lethality in Cancer
2025Open Access
Supplementary Figure S3 from Ubiquitinated PCNA Drives USP1 Synthetic Lethality in Cancer
2025Open Access
Supplementary Figure S5 from Ubiquitinated PCNA Drives USP1 Synthetic Lethality in Cancer
2025Open Access
Supplementary Figure S4 from Ubiquitinated PCNA Drives USP1 Synthetic Lethality in Cancer
2025Open Access
Supplementary Data from Ubiquitinated PCNA Drives USP1 Synthetic Lethality in Cancer
2025Open Access
Supplementary Figure S1 from Ubiquitinated PCNA Drives USP1 Synthetic Lethality in Cancer
2025Open Access
Discovery of Kinesin KIF18A Inhibitor ATX020: Tactical Application of Silicon Atom Replacement
ACS Medicinal Chemistry Letters·2025· 1 cited
Discovery of TNG-6132, a potent, selective, and orally bioavailable USP1 inhibitor
Bioorganic & Medicinal Chemistry Letters·2025
Discovery of ATX968: An Orally Available Allosteric Inhibitor of DHX9
Journal of Medicinal Chemistry·2025· 6 citedOpen Access
Abstract 1758: ATX-559, a first in class DHX9 inhibitor, and targeted therapeutic for molecularly defined tumors with genomic instability and replicative stress
Cancer Research·2025· 1 cited
Abstract 3784: Activity of the novel KIF18A inhibitor, ATX-295, is enriched in whole genome doubled ovarian cancer pre-clinical models
Cancer Research·2025· 1 cited
Supplementary Data Figure 2 from A Potent, Selective, Small-Molecule Inhibitor of DHX9 Abrogates Proliferation of Microsatellite Instable Cancers with Deficient Mismatch Repair
2025Open Access
Supplementary Data Figure 2 from A Potent, Selective, Small-Molecule Inhibitor of DHX9 Abrogates Proliferation of Microsatellite Instable Cancers with Deficient Mismatch Repair
2025Open Access
Supplementary Data Figure 3 from A Potent, Selective, Small-Molecule Inhibitor of DHX9 Abrogates Proliferation of Microsatellite Instable Cancers with Deficient Mismatch Repair
2025Open Access
Supplementary Data Table 2 from A Potent, Selective, Small-Molecule Inhibitor of DHX9 Abrogates Proliferation of Microsatellite Instable Cancers with Deficient Mismatch Repair
2025Open Access
Supplementary Data Figure 4 from A Potent, Selective, Small-Molecule Inhibitor of DHX9 Abrogates Proliferation of Microsatellite Instable Cancers with Deficient Mismatch Repair
2025Open Access
Supplementary Data Figure 4 from A Potent, Selective, Small-Molecule Inhibitor of DHX9 Abrogates Proliferation of Microsatellite Instable Cancers with Deficient Mismatch Repair
2025Open Access
Supplementary Data Table 3 from A Potent, Selective, Small-Molecule Inhibitor of DHX9 Abrogates Proliferation of Microsatellite Instable Cancers with Deficient Mismatch Repair
2025Open Access
Supplementary Data Figure 1 from A Potent, Selective, Small-Molecule Inhibitor of DHX9 Abrogates Proliferation of Microsatellite Instable Cancers with Deficient Mismatch Repair
2025Open Access
page 1 of 4Next →

Frequent Co-authors

P. Ann Boriack‐Sjodin(24), Robert A. Copeland(24), Kenneth W. Duncan(23), Shane M. Buker(22), Serena J. Silver(22), Stephen J. Blakemore(22), Kevin E. Knockenhauer(21), Brian A. Sparling(21), Jennifer Castro(20), Matthew H. Daniels(20), Young‐Tae Lee(20), John P. Maxwell(19), Alan Huang(19), Julie Liu(19), Shihua Yao(19), E. Allen Sickmier(19), Scott Ribich(19), April Case(18), Erik Wilker(17), Douglas A. Whittington(17)